Maspin, E-selectin, and P-selectin expressions in papillary thyroid carcinomas and their correlation with prognostic parameters

Pathology Research and Practice

Volumn 204, Issue 10, 2008, Pages 743-750

  Bal, Nebil ^a   Kocer, N Emrah ^a   Ertorer, M Eda ^a   Canpolat, E Tuba ^a   Kayaselcuk, Fazilet ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

E selectin; Maspin; P selectin; Papillary carcinoma; Thyroid

Indexed keywords

CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; MASPIN; PADGEM PROTEIN; SERINE PROTEINASE INHIBITOR; TUMOR SUPPRESSOR PROTEIN;

ADULT; ANGIOGENESIS; ARTICLE; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; FEMALE; HUMAN; INHIBITION KINETICS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; METASTASIS POTENTIAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN INTERACTION; SOFT TISSUE METASTASIS; STATISTICAL ANALYSIS; THYROID PAPILLARY CARCINOMA;

ADULT; CARCINOMA, PAPILLARY; E-SELECTIN; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; P-SELECTIN; PROGNOSIS; SERPINS; THYROID NEOPLASMS;

EID: 52049124537     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2008.04.016     Document Type: Article

References (37)

1. Bass R., Fernández A.M., and Ellis V. Maspin inhibits cell migration in the absence of protease inhibitory activity. J. Biol. Chem. 6 (2002) 46845-46848
2. Boltze C., Schneider-Stock R., Meyer F., et al. Maspin in thyroid cancer: its relationship with p53 and clinical outcome. Oncol. Rep. 10 (2003) 1783-1787
3. Boltze C., Schneider-Stock R., Quednow C., et al. Proteome analysis identified maspin as a special feature of papillary thyroid carcinoma. Int. J. Oncol. 23 (2003) 1323-1328
4. Chen J.L., Chen W.X., Zhu J.S., et al. Effect of P-selectin monoclonal antibody on metastasis of gastric cancer and immune function. World J. Gastroenterol. 9 (2003) 1607-1610
5. Coskun U., Sancak B., Sen I., et al. Serum P-selectin, soluble vascular cell adhesion molecule-I (s-VCAM-I) and soluble intercellular adhesion molecule-I (s-ICAM-I) levels in bladder carcinoma patients with different stages. Int. Immunopharmacol. 6 (2006) 672-677
6. Dimitroff C.J., Descheny L., Trujillo N., et al. Identification of leukocyte E-selectin ligands, P selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells. Cancer Res. 1 (2005) 5750-5760
7. Ferroni P., Roselli M., Martini F., et al. Prognostic value of soluble P-selectin levels in colorectal cancer. Int. J. Cancer 1 (2004) 404-408
8. Garcia J., Callewaert N., and Borsig L. P-selectin mediates metastatic progression through binding to sulfatides on tumor cells. Glycobiology 17 (2007) 185-196
9. Groves R.W., Allen M.H., Ross E.L., et al. Expression of selectin ligands by cutaneous squamous cell carcinoma. Am. J. Pathol. 143 (1993) 1220-1225
10. Hirai K., Koizumi K., Haraguchi S., et al. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer. Ann. Thorac. Surg. 79 (2005) 248-253
11. Iezzi G., Piattelli A., Rubini C., et al. Maspin expression in oral squamous cell carcinoma. J. Craniofac. Surg. 18 (2007) 1039-1043
12. Ito Y., Yoshida H., Tomoda C., et al. Maspin expression is directly associated with biological aggressiveness of thyroid carcinoma. Thyroid 14 (2004) 13-18
13. Ke J.J., Shao Q.S., and Ling Z.Q. Expression of E-selectin, integrin beta1 and immunoglobulin superfamily member in human gastric carcinoma cells and its clinicopathologic significance. World J. Gastroenterol. 14 (2006) 3609-3611
14. Maass N., Hojo T., Ueding M., et al. Expression of the tumor suppressor gene Maspin in human pancreatic cancers. Clin. Cancer Res. 7 (2001) 812-817
15. Martins M.T., Altemani A., Freitas L., and Araújo V.C. Maspin expression in carcinoma ex pleomorphic adenoma. J. Clin. Pathol. 58 (2005) 1311-1314
16. Mohsin S.K., Zhang M., Clark G.M., and Craig D. Allred, Maspin expression in invasive breast cancer: association with other prognostic factors. J. Pathol. 199 (2003) 432-435
17. Murai S., Maesawa C., Masuda T., and Sugiyama T. Aberrant maspin expression in human endometrial cancer. Cancer Sci. 97 (2006) 883-888
18. Nakagawa M., Katakura H., Adachi M., et al. Maspin expression and its clinical significance in non-small cell lung cancer. Ann. Surg. Oncol. 13 (2006) 1517-1523
19. Nakashima M., Eguchi K., Ishikawa N., et al. Expression of adhesion molecule ICAM-1 (CD54) in thyroid papillary adenocarcinoma. Endocrinol. Invest. 17 (1994) 843-848
20. Navarro R.L., Martins M.T., and de Araújo V.C. Maspin expression in normal and neoplastic salivary gland. J. Oral Pathol. Med. 33 (2004) 435-440
21. Nooijen P.T., Westphal J.R., Eggermont A.M., et al. Endothelial P-selectin expression is reduced in advanced primary melanoma and melanoma metastasis. Am. J. Pathol. 152 (1998) 679-682
22. Ogasawara S., Maesawa C., Yamamoto M., et al. Disruption of cell-type-specific methylation at the maspin gene promoter is frequently involved in undifferentiated thyroid cancers. Oncogene 5 (2004) 1117-1124
23. Peeters C.F., Ruers T.J., Westphal J.R., and de Waal R.M. Progressive loss of endothelial P-selectin expression with increasing malignancy in colorectal cancer. Lab. Invest. 85 (2005) 248-256
24. Schwarz S., Ettl T., Kleinsasser N., et al. Loss of Maspin expression is a negative prognostic factor in common salivary gland tumors. Oral Oncol. 11 (2007) (Epub ahead of print)
25. Secord A.A., Lee P.S., Darcy K.M., et al. Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a gynecologic oncology group study. Gynecol. Oncol. 101 (2006) 390-397
26. Shams T.M., Samaka R.M., and Shams M.E. Maspin protein expression: a special feature of papillary thyroid carcinoma. J. Egypt Natl. Cancer Inst. 18 (2006) 274-280
27. Sheng S., Pemberton P.A., and Sager R. Production, purification, and characterization of recombinant maspin proteins. J. Biol. Chem. 9 (1994) 30988-30993
28. Sheng S., Carey J., Seftor E.A., et al. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc. Natl. Acad. Sci. USA 15 (1996) 11669-11674
29. Solomon L.A., Munkarah A.R., Schimp V.L., et al. Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer. Gynecol. Oncol. 101 (2006) 385-389
30. Son H.J., Sohn T.S., Song S.Y., Lee J.H., and Rhee J.C. Maspin expression in human gastric adenocarcinoma. Pathol. Int. 52 (2002) 508-513
31. Sood A.K., Fletcher M.S., Gruman L.M., et al. The paradoxical expression of maspin in ovarian carcinoma. Clin. Cancer Res. 8 (2002) 2924-2932
32. Wang M.C., Yang Y.M., Li X.H., Dong F., and Li Y. Maspin expression and its clinicopathological significance in tumorigenesis and progression of gastric cancer. World J. Gastroenterol. 1 (2004) 634-637
33. Xia W., Lau Y.K., Hu M.C., et al. High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma. Oncogene 11 (2000) 2398-2403
34. Yu M., Zheng H., Tsuneyama K., et al. Paradoxical expression of maspin in gastric carcinomas: correlation with carcinogenesis and progression. Hum. Pathol. 38 (2007) 1248-1255
35. Zhang M., Maass N., Magit D., and Sager R. Transactivation through Ets and Ap1 transcription sites determines the expression of the tumor-suppressing gene maspin. Cell Growth Differ. 8 (1997) 179-186
36. Zhang M., Volpert O., Shi Y.H., and Bouck N. Maspin is an angiogenesis inhibitor. Nat. Med. 6 (2000) 196-199
37. Zou Z., Anisowicz A., Hendrix M.J., et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 28 (1994) 526-529